ENDRA Life Sciences Inc. (NDRA) financial statements (2022 and earlier)
Company profile
| Business Address |
3600 GREEN COURT ANN ARBOR, MI 48105 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 3845 - Electromedical and Electrotherapeutic Apparatus (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | 6/30/2020 Q2 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 9,462 | 11,793 | 14,043 | 16,843 | 7,227 | 3,793 | 749 | ||
| Cash and cash equivalents | 9,462 | 11,793 | 14,043 | 16,843 | 7,227 | 3,793 | 749 | ||
| Inventory, net of allowances, customer advances and progress billings | 1,285 | 1,500 | 1,325 | 727 | 590 | 323 | 341 | ||
| Inventory | 1,285 | 1,500 | 1,325 | 727 | 590 | 323 | 341 | ||
| Prepaid expense | 1,177 | 969 | 776 | 391 | 562 | 1,064 | |||
| Other current assets | 6 | 6 | 6 | 101 | 122 | ||||
| Total current assets: | 10,746 | 14,470 | 16,343 | 18,351 | 8,214 | 4,780 | 2,275 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 643 | 676 | 708 | 322 | 339 | 356 | 373 | ||
| Property, plant and equipment | 131 | 162 | 192 | 226 | 212 | 226 | 215 | ||
| Other noncurrent assets | 6 | ||||||||
| Total noncurrent assets: | 775 | 844 | 900 | 547 | 551 | 582 | 587 | ||
| TOTAL ASSETS: | 11,521 | 15,314 | 17,243 | 18,899 | 8,765 | 5,361 | 2,863 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 1,411 | 1,149 | 582 | 910 | 1,028 | 969 | |||
| Accounts payable | 791 | 748 | 448 | 403 | 874 | 495 | |||
| Accrued liabilities | 205 | 315 | |||||||
| Employee-related liabilities | 101 | 196 | 134 | 48 | 154 | 159 | |||
| Other undisclosed accounts payable and accrued liabilities | 519 | 459 | |||||||
| Other undisclosed current liabilities | 428 | 1,638 | 184 | 76 | 371 | 271 | |||
| Total current liabilities: | 1,411 | 1,577 | 1,638 | 766 | 987 | 1,399 | 1,240 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 518 | 581 | 615 | 281 | 609 | 628 | 645 | ||
| Long-term debt, excluding current maturities | 581 | 615 | 28 | 337 | 337 | 337 | |||
| Operating lease, liability | 518 | 252 | 272 | 290 | 308 | ||||
| Other undisclosed noncurrent liabilities | (252) | (290) | (308) | ||||||
| Total noncurrent liabilities: | 518 | 581 | 615 | 281 | 609 | 628 | 645 | ||
| Total liabilities: | 2,448 | 2,158 | 2,253 | 1,047 | 1,596 | 2,026 | 1,886 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | 10,784 | 13,156 | 14,990 | 17,852 | 7,169 | 3,335 | 977 | ||
| Common stock | 4 | 4 | 4 | 3 | 3 | 2 | |||
| Additional paid in capital | 78,695 | 77,839 | 77,461 | 64,494 | 58,282 | 52,228 | |||
| Accumulated deficit | (68,691) | (65,586) | (62,928) | (59,729) | (57,338) | (55,088) | (51,434) | ||
| Other undisclosed stockholders' equity attributable to parent | 79,475 | 43 | 75 | 116 | 11 | 139 | 181 | ||
| Total stockholders' equity: | 10,784 | 13,156 | 14,990 | 17,852 | 7,169 | 3,335 | 977 | ||
| TOTAL LIABILITIES AND EQUITY: | 13,232 | 15,314 | 17,243 | 18,899 | 8,765 | 5,361 | 2,863 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | 6/30/2020 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (3,072) | (2,651) | (3,200) | (2,576) | (2,254) | (3,255) | (2,891) | |
| Operating loss: | (3,072) | (2,651) | (3,200) | (2,576) | (2,254) | (3,255) | (2,891) | |
| Nonoperating income (expense) | (33) | (8) | 1 | 307 | 4 | (3) | (3) | |
| Other nonoperating income (expense) | (33) | (8) | 1 | (2) | 4 | (3) | 1 | |
| Interest and debt expense | 309 | |||||||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | (309) | |||||||
| Loss from continuing operations before equity method investments, income taxes: | (3,413) | (2,658) | (3,199) | (1,961) | (2,251) | (3,258) | (2,894) | |
| Other undisclosed income (loss) from continuing operations before income taxes | 309 | (309) | ||||||
| Loss before gain (loss) on sale of properties: | (3,105) | (2,658) | (3,199) | (2,269) | (2,251) | (3,258) | (2,894) | |
| Other undisclosed net income | 22,463 | |||||||
| Net income (loss): | 19,358 | (2,658) | (3,199) | (2,269) | (2,251) | (3,258) | (2,894) | |
| Other undisclosed net loss attributable to parent | (22,463) | |||||||
| Net loss attributable to parent: | (3,105) | (2,658) | (3,199) | (2,269) | (2,251) | (3,258) | (2,894) | |
| Other undisclosed net loss available to common stockholders, basic | (121) | (396) | ||||||
| Net loss available to common stockholders, diluted: | (3,105) | (2,658) | (3,199) | (2,390) | (2,251) | (3,654) | (2,894) | |
Comprehensive Income ($ in thousands)
| 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | 6/30/2020 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 19,358 | (2,658) | (3,199) | (2,269) | (2,251) | (3,258) | (2,894) | |
| Comprehensive income (loss), net of tax, attributable to parent: | 19,358 | (2,658) | (3,199) | (2,269) | (2,251) | (3,258) | (2,894) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.